Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Deffered Revenue: 2022-2023

Historic Non-Current Deffered Revenue for Stoke Therapeutics (STOK) over the last 2 years, with Dec 2023 value amounting to $33.1 million.

  • Stoke Therapeutics' Non-Current Deffered Revenue rose 3.22% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 3.22%. This contributed to the annual value of $33.1 million for FY2023, which is 10.26% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Non-Current Deffered Revenue of $33.1 million as of FY2023, which was down 10.26% from $36.9 million recorded in FY2022.
  • Stoke Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $36.9 million during FY2022, with a 5-year trough of $33.1 million in FY2023.
  • Over the past 2 years, Stoke Therapeutics' median Non-Current Deffered Revenue value was $35.0 million (recorded in 2022), while the average stood at $35.0 million.
  • Data for Stoke Therapeutics' Non-Current Deffered Revenue shows a maximum YoY declined of 10.26% (in 2023) over the last 5 years.
  • Yearly analysis of 2 years shows Stoke Therapeutics' Non-Current Deffered Revenue stood at $36.9 million in 2022, then fell by 10.26% to $33.1 million in 2023.